Pfizer Inc. (NYSE:PFE) Shares Sold by PSI Advisors LLC

PSI Advisors LLC decreased its holdings in Pfizer Inc. (NYSE:PFE) by 1.4% during the 3rd quarter, HoldingsChannel reports. The fund owned 27,438 shares of the biopharmaceutical company’s stock after selling 397 shares during the quarter. PSI Advisors LLC’s holdings in Pfizer were worth $794,000 as of its most recent SEC filing.

Several other institutional investors have also modified their holdings of PFE. Global Assets Advisory LLC acquired a new position in shares of Pfizer in the first quarter worth about $725,000. Atlas Capital Advisors LLC lifted its stake in shares of Pfizer by 54.4% in the first quarter. Atlas Capital Advisors LLC now owns 1,702 shares of the biopharmaceutical company’s stock worth $47,000 after acquiring an additional 600 shares in the last quarter. Sovereign Financial Group Inc. lifted its stake in shares of Pfizer by 12.2% in the first quarter. Sovereign Financial Group Inc. now owns 16,929 shares of the biopharmaceutical company’s stock worth $470,000 after acquiring an additional 1,837 shares in the last quarter. Wealthcare Advisory Partners LLC lifted its stake in shares of Pfizer by 149.7% in the first quarter. Wealthcare Advisory Partners LLC now owns 129,868 shares of the biopharmaceutical company’s stock worth $3,604,000 after acquiring an additional 77,868 shares in the last quarter. Finally, Edge Wealth Management LLC lifted its stake in shares of Pfizer by 2.0% in the first quarter. Edge Wealth Management LLC now owns 260,180 shares of the biopharmaceutical company’s stock worth $7,220,000 after acquiring an additional 5,121 shares in the last quarter. Institutional investors and hedge funds own 68.36% of the company’s stock.

Analysts Set New Price Targets

Several analysts recently weighed in on the company. Sanford C. Bernstein assumed coverage on Pfizer in a report on Thursday, October 17th. They issued a “market perform” rating and a $32.00 price objective for the company. Daiwa Capital Markets raised Pfizer from a “neutral” rating to an “outperform” rating and boosted their price objective for the company from $28.00 to $34.00 in a report on Wednesday, August 7th. Cantor Fitzgerald reissued an “overweight” rating and issued a $45.00 price objective on shares of Pfizer in a report on Wednesday. Barclays boosted their price objective on Pfizer from $30.00 to $32.00 and gave the company an “equal weight” rating in a report on Wednesday, July 31st. Finally, Daiwa America raised Pfizer from a “moderate buy” rating to a “strong-buy” rating in a report on Wednesday, August 7th. Seven investment analysts have rated the stock with a hold rating, six have given a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $33.91.

Pfizer Stock Performance

Shares of NYSE PFE opened at $28.84 on Thursday. The company has a current ratio of 0.86, a quick ratio of 0.60 and a debt-to-equity ratio of 0.65. The stock has a 50 day simple moving average of $29.07 and a 200-day simple moving average of $28.48. The company has a market cap of $163.42 billion, a PE ratio of -481.00, a P/E/G ratio of 1.02 and a beta of 0.67. Pfizer Inc. has a 12-month low of $25.20 and a 12-month high of $31.54.

Pfizer (NYSE:PFE) last issued its quarterly earnings data on Tuesday, July 30th. The biopharmaceutical company reported $0.60 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.46 by $0.14. The business had revenue of $13.28 billion during the quarter, compared to the consensus estimate of $12.96 billion. Pfizer had a positive return on equity of 8.42% and a negative net margin of 4.66%. The business’s revenue was up 2.1% on a year-over-year basis. During the same period in the previous year, the firm posted $0.67 earnings per share. On average, equities research analysts forecast that Pfizer Inc. will post 2.66 EPS for the current year.

Pfizer Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Monday, December 2nd. Shareholders of record on Friday, November 8th will be given a $0.42 dividend. The ex-dividend date of this dividend is Friday, November 8th. This represents a $1.68 dividend on an annualized basis and a yield of 5.83%. Pfizer’s dividend payout ratio (DPR) is -2,800.00%.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.